Current research into myeloma
Help us beat cancer sooner
Our life-saving work relies on the money you give us.
Donate now and together we can save more lives by beating cancer sooner.
Saving lives through our research
Our research into myeloma ranges from investigating how rogue cells in the bone marrow develop into cancer to clinical trials of new and better treatments. Below are some examples of what our researchers are doing right now.
Our current researchers
Developing new treatments
In Leeds, Professor Gordon Cook is running several clinical trials to improve treatment for patients with myeloma, a type of blood cancer. He is currently leading the UKMRA Myeloma XII (ACCoRD) study. It’s looking at the benefits of adding a drug called ixazomib to stem cell transplants for people with myeloma whose disease has returned.
Helping young and old patients
The International Myeloma Working Group has developed a ‘patient frailty score’. It could help doctors predict how well older people with myeloma will tolerate treatment – and if it will work. Professor Graham Jackson in Newcastle and Professor Gordon Cook in Leeds are using this score as part of a clinical trial that includes older patients. It’s testing if a combination of two new myeloma drugs will improve treatment for all myeloma patients, both young and old.
Finding the best treatment for each patient
Professor Kwee Yong and her team in London are running a clinical trial called CARDAMON. It’s asking the question ‘what is the best way to treat people who have just been diagnosed with myeloma?’ The team are also investigating changes in the genetic makeup of each patient’s cancer as they’re treated. By doing this, they hope to find better ways to treat the disease in the future.
Studying 'sleeping' cells
Myeloma arises from rogue ‘sleeping’ cells which get woken up and develop into cancer. Professor Reuben Tooze in Leeds is studying exactly how these cells stay ‘asleep’ and how they’re woken up, allowing them to grow and multiply. His research could lead to ways to spot when these cells are about to wake-up and could help find new treatments for when they do.